Traveling in Europe: Should Mosquito Risks Be on Your Radar?

Published Date: 25 Jun 2026

Travel medicine specialists say that mosquito protection deserves the same attention as sunscreen because vector-borne infections become more common in Europe.

Read Full News

Latest News

Warning: Patient's Itchy Swollen Skin Patches Were Not Infectious Cellulitis

Five years of inappropriate antibiotic treatment finally ended after proper diagnosis

10-Year Data Back Early Start to Biologics in Arthritic Diseases

— Sustained drug-free remission common in spondyloarthritis patients treated with golimumab

Shingles Recurrence or Something Worse?

Bedside skin punch biopsy proved crucial

Skin Problems, Kidney Complaints, and Venous Issues Spike During Heat Waves

Study suggests attention to heat-related problems besides heat stroke

First Oral Option for Dermatomyositis Gets FDA Green Light

Brepocitinib significantly improved overall symptom status in a phase III trial

A Call to End Routine Laboratory Monitoring for Patients on Isotretinoin

Streamlined testing still overkill given lack of evidence for hepatotoxicity, pancreatitis

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

Five years of inappropriate antibiotic treatment finally ended after proper diagnosis

— Sustained drug-free remission common in spondyloarthritis patients treated with golimumab

Bedside skin punch biopsy proved crucial

Study suggests attention to heat-related problems besides heat stroke

Brepocitinib significantly improved overall symptom status in a phase III trial

Streamlined testing still overkill given lack of evidence for hepatotoxicity, pancreatitis

News All Time

US Regulators Urge More Research on Testosterone Therapy for Women as Experts Debate Benefits, Risks

US health regulators on Thursday called for more data on testosterone therapies for women, with FDA officials urging manufacturers to conduct studies that could support...

FDA Grants Priority Review for Diabetic Foot Ulcer Therapy

The FDA has granted priority review for a novel wound-healing therapy for Wagner Grade 1 diabetic foot ulcers.

Pennsylvania Measles Cases Top 700 After Four Outbreak-related Deaths Reported

The Pennsylvania Department of Health on Wednesday reported 731 measles cases, up 38 from Monday's ⁠update, as the outbreak continued to spread in the state at the center of...

Fear of Relapse Burdens Patients With Vitiligo

Nearly half of patients with vitiligo who achieve repigmentation fear losing treatment gains, with relapse-related anxiety affecting psychological well-being even when skin improvement is maintained.

Adding IVIG to Prednisone Boosts Outcomes in IIMs

IVIG plus high-dose prednisone leads to improved disease activity and a faster response in newly diagnosed idiopathic inflammatory myopathies, but clotting remains a concern.

Smoke Exposure Tied to HS Risk in Children and Teens

Both passive and active exposure were associated with increased odds of diagnosis in pediatric and adolescent patients with hidradenitis suppurativa, a study reports.

A Decade After Mercury Ban, Toxic Skin Bleachers Still Offered on Top Retailers' Websites

(Removes errant quote marks in paragraph 14)

Pennsylvania Measles-associated Deaths Climb to Four as Outbreak Grows

The Pennsylvania Department of Health on Tuesday reported two more measles-associated deaths, both in unvaccinated individuals, bringing the state's total fatalities linked...

FDA Grants Priority Review to Zasocitinib for Psoriasis

Zasocitinib is also being evaluated in phase 3 studies for psoriatic arthritis and in phase 2 studies for Crohn’s disease, ulcerative colitis, vitiligo, and hidradenitis suppurativa.

Serious Infections Lower With Anifrolumab in CLE Patients

Anifrolumab, approved for systemic lupus, is currently being evaluated in a phase 3 study in patients with cutaneous lupus erythematosus.

COVID, 6 Years on: The Pandemic’s Long Clinical Shadow

Although acute COVID is generally less severe today, long COVID, limited treatment options, and ongoing controversy still define the pandemic’s aftermath.

Prior Keratinocyte Carcinoma Tied to Mucosal Melanoma

A history of keratinocyte carcinoma was associated with more than four times the odds of mucosal melanoma, study reports.

Trust in Measles Vaccines Falls in US, Reuters Ipsos Poll Finds

Americans' trust in vaccines for deadly childhood diseases including measles has fallen in recent years, a new Reuters/Ipsos poll found, a troubling sign for the country as...

Arizona Accuses L'Oreal Of Concealing Cancer Risks Linked to Hair Relaxers

Arizona has sued L'Oreal SA and its U.S. subsidiary, alleging the cosmetics company hid evidence that its hair relaxer products could cause cancer ⁠in women, as it faces...

Pembrolizumab Benefits Persist in Cervical Cancer

After 5 years of follow-up, pembrolizumab plus chemotherapy continues to demonstrate sustained survival advantages in patients with persistent, recurrent, or metastatic cervical cancer.

Criteria for Prescribing Testosterone: Who Qualifies?

A Brazilian multidisciplinary consensus sets thresholds for the diagnosis and treatment while emphasizing symptom assessment, repeated testing, and attention to the underlying causes.

Recommended News For You

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Researchers discover that children who survive cancer have socioeconomic challenges.

Admissions, medical colleges, fees, and eligibility requirements information for the DNB Post Diploma in Radiation Oncology.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Parkinson patient's gait is restored by a spinal cord stimulator.

Recommended Articles For You

Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology 

Age-Related Changes in Platelet Reactivity: Mechanisms, Clinical Implications, and Management Strategies 

The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring 

Connected Oncology Pharmacy Workflow Platforms: Clinical Integration, Safety, and Future Directions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

CAR Natural Killer Cell Therapy Shows Promise in B-Cell Lymphomas

2.

Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.

3.

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

4.

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

5.

Study confirms link between breast density, higher breast cancer risk

1.

Ferroptosis-Modulating Therapies for Treatment-Resistant Malignancies

2.

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals

3.

Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production

4.

Case-Based Learning: Reasoning Through New Functional Changes During Long-Term Cancer Survivorship

5.

Drug Exposure During Cytopenia: Clinical Considerations and Evidence-Based Management

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

2.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

3.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

4.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

5.

Coordinating Supportive Care During Cancer Treatment Delays

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot